Plain-English translation of NCT07694375 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing CA201A, an eye drop solution containing vitamin C, to see if it can protect the innermost layer of your cornea (called the endothelium) from damage during cataract surgery. About 200 people who need cataract surgery will receive either the medication or a placebo (inactive drops), starting one week before surgery and continuing for four weeks afterward. Researchers want to learn whether this treatment can prevent the loss of important corneal cells that can sometimes occur during the surgical procedure.
During cataract surgery, the delicate cells lining the inner surface of the cornea can be accidentally damaged, which may affect vision quality over time. This study exists to find out whether the medication can provide protective effects and reduce this type of cell loss.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would start taking the study eye drops (or placebo) four times daily for one week before your cataract surgery. You'll continue the same dosing schedule on the day of surgery and for four weeks afterward. Your participation includes a screening visit about three weeks before surgery, the surgery itself (which follows normal procedures), and follow-up visits through week 12 after surgery to check your cornea's health and measure how many endothelial cells remain. The entire study lasts approximately 12 weeks from your surgery date.
AI-generated summary from trial data ยท Aug 24, 2026 ยท Not medical advice
Australia